May 2021 - QuartzBio

May 5, 2021 — As the data generated during a modern clinical trial has dramatically expanded, sponsors must continuously evaluate novel approaches to help bridge the gap between millions of data points and breakthrough scientific insights (a goal we describe as delivering Translational Intelligence). One such example is assessing signatures of “hot” and “cold” tumors.

QuartzBio is the only company purpose-built to deliver end-to-end Sample and Biomarker Intelligence for clinical-stage biopharma teams. Powered by a network of domain-specific AI agents, our solutions transform fragmented data into actionable intelligence, enabling conversational insights into your unified ecosystem of sample, clinical, and biomarker data.